Muna Qayed, Urvi Kapoor, Scott Gillespie, Adrianna Westbrook, Paibel Aguayo-Hiraldo, A Francis Ayuk, Mina Aziz, Janna Baez, Hannah Choe, Zachariah DeFilipp, Aaron Etra, Stephan A Grupp, Elizabeth Hexner, Ernst Holler, William J Hogan, Steven Kowalyk, Pietro Merli, George Morales, Ryotaro Nakamura, Michael A Pulsipher, Tal Schechter, Jay Shah, Nikolaos Spyrou, Hrishikesh K Srinagesh, Matthias Wölfl, Gregory Yanik, Rachel Young, Carrie L Kitko, James L M Ferrara, John E Levine
Acute graft versus host disease (GVHD) is a common and serious complication of allogeneic hematopoietic cell transplantation (HCT) in children but overall clinical grade at onset only modestly predicts response to treatment and survival outcomes. Two tools to assess risk at initiation of treatment were recently developed. The Minnesota risk system stratifies children for risk of non-relapse mortality (NRM) according to the pattern of GVHD target organ severity. The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm of two serum biomarkers (ST2 and REG3α) predicts NRM in adult patients but has not been validated in a pediatric population...
March 26, 2024: Transplantation and cellular therapy